Animal models and therapeutic molecules

Patent metadata

Field	Value
Publication number	US-9504236-B2
Application number	US-201514935010-A
Country	US
Kind code	B2
Filing date	Nov 6, 2015
Priority date	Jul 8, 2009
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

The invention pertains to a transgenic non-human mammal which contains a chimeric immunoglobulin locus containing human variable region gene segments at an endogenous Ig locus operatively linked to non-human mammalian constant region genes, and methods to produce chimeric antibodies therefrom.

First claim

We claim:

1. A transgenic mouse having a genome with homozygous immunoglobulin heavy chain (IgH) locus,
wherein said homozygous IgH locus comprises unrearranged human immunoglobulin heavy chain (IgH) variable region (VH) DNA comprising one or more human IgH V gene segments, one or more human D gene segments, one or more human JH gene segments and human intronic DNA contiguous with mouse intronic DNA at an endogenous IgH locus upstream of an enhancer and a constant (C) region comprising an endogenous CH gene segment,
wherein said C region comprises mouse Cμ and said human variable region gene segments are operably linked to said C region to permit rearrangement and expression of IgM heavy chain polypeptide comprising a human variable region and a mouse μ constant region,
wherein in said transgenic mouse expression of IgH heavy chains comprising endogenous mouse variable regions is reduced or prevented;
wherein said mouse comprises IgH-VDJCμ transcripts encoding said chimeric IgM polypeptide and wherein said IgM comprises human CDR-H3, and said IgH-VDJCμ transcripts comprise transcripts encoding human variable region CDR-H3 lengths of 19 to 22 amino acids,
wherein the mean frequency of said transcripts encoding CDR-H3 lengths selected from the group consisting of 18 and 19 amino acids present in said IgH-VDJCμ transcripts of said mouse is between 5% and 10%.

2. The transgenic mouse of claim 1 , wherein said human intronic DNA is contiguous with said mouse intronic DNA at a human DNA/mouse DNA joinder point and wherein said one or more human JH gene segments comprises a 3′-most JH gene segment contiguous with said human intronic DNA, wherein said 3′-most JH gene segment is less than 2 kb upstream of said joinder point.

3. The transgenic mouse of claim 2 , wherein said 3′-most JH gene segment is less than 1 kb upstream of said joinder point.

4. The transgenic mouse of claim 2 , wherein said 3′-most JH gene segment comprises a human JH6 gene segment.

5. The transgenic mouse of claim 2 , wherein DNA between said joinder point and said enhancer comprises mouse JC intronic DNA, and wherein said mouse JC intronic DNA comprises less than the complete mouse JC intron.

6. The transgenic mouse of claim 2 , wherein DNA between said joinder point and said enhancer comprises mouse 129 strain DNA.

7. The transgenic mouse of claim 1 , wherein said genome comprises all or part of mouse heavy chain variable region inverted with respect to said heavy chain constant region to render expression of Ig heavy chains comprising a mouse variable region reduced or prevented.

8. The transgenic mouse of claim 1 , wherein said genome comprises all or part of mouse heavy chain variable region away from said heavy chain constant region to render expression of Ig heavy chains comprising a mouse variable region reduced or prevented.

9. The transgenic mouse of claim 1 , wherein all or part of the mouse heavy chain variable region is absent in said genome to render expression of Ig heavy chains comprising a mouse variable region reduced or prevented.

10. The transgenic mouse of claim 1 , wherein said mouse is functional to produce antibody isotypes IgM and IgG specific for an antigen, said antibody isotype heavy chain comprising a human heavy chain variable region.

11. The transgenic mouse of claim 1 , wherein said IgH-VDJCμ transcripts encoding a human variable region comprise a CDR-H3 length of 14-19 amino acids.

12. The transgenic mouse of claim 11 , wherein the frequency of transcripts encoding a CDR-H3 length of 19 amino acids in said IgH-VDJCμ transcripts of said mouse is 5%.

13. The transgenic mouse of claim 11 , wherein the frequency of transcripts encoding a CDR-H3 length of 19 amino acids in said IgH-VDJCμ transcripts of said mouse is less than transcripts encoding a CDR-H3 length of 17 amino acids and more than transcripts encoding a CDR-H3 length of 20 amino acids.

14. The transgenic mouse of claim 11 , wherein the frequency of transcripts encoding a CDR-H3 length of 19 amino acids in said IgH-VDJCμ transcripts of said mouse is less than transcripts encoding a CDR-H3 length of 17 amino acids.

15. The transgenic mouse of claim 11 , wherein the mean frequency of transcripts encoding CDR-H3 lengths between 14-19 amino acids in said IgH-VDJCμ transcripts of said mouse is between 5% and 10%.

Assignees

• Kymab Limited; The Bennet Building (B930)
• Kymab Ltd

Inventors

• Bradley Allan
• Lee E-Chiang
• Liang Qi
• Wang Wei

Classifications

• C12N2015/8518

  expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles · CPC title

• C07K16/462 Primary

  Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another · CPC title

• C07K16/1282

  Clostridium (G) · CPC title

• A01K67/0278 Primary

  Knock-in vertebrates, e.g. humanised vertebrates · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title